Comment
doi: 10.1016/j.ccell.2015.02.009.
Vismodegib resistance in basal cell carcinoma: not a smooth fit
Affiliations
- PMID: 25759014
- DOI: 10.1016/j.ccell.2015.02.009
Item in Clipboard
Comment
Vismodegib resistance in basal cell carcinoma: not a smooth fit
Cancer Cell.
.
Free article
Abstract
In this issue of Cancer Cell, two complementary papers by Atwood and colleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO) inhibitor vismodegib frequently harbor SMO mutations that limit drug binding, with mutations at some sites also increasing basal SMO activity.
Copyright © 2015 Elsevier Inc. All rights reserved.
Comment on
-
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.Cancer Cell. 2015 Mar 9;27(3):327-41. doi: 10.1016/j.ccell.2015.02.001. Cancer Cell. 2015. PMID: 25759019 Free PMC article.
-
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.Cancer Cell. 2015 Mar 9;27(3):342-53. doi: 10.1016/j.ccell.2015.02.002. Cancer Cell. 2015. PMID: 25759020 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
